With a strong operational history, the company is committed to meeting all their needs in the entire journey of eye treatment of its patients. As of September 30, 2024, the company's network consisted of 209 features. The Crisil MI&A report also reported that the company had the most eye care service facilities compared to its listed and non-listed competitors in India at the time. According to the Red Herring Prospectus (RHP), among the publicly listed competitors of the company, Apollo Hospitals Enterprise's P/E is 107.11, P/E of Max Healthcare Institute is P/E 95.88, P/E of Fortis Healthcare is 82.11, Global Health of Global Health The P/E is 57.49, Narayan Hridayalaya's P/E is 33.14, Krishna Institute of Medical Sciences P/E is 79.79, Ester DM Healthcare's P/E is 136.07, and Rainbow Children's Medicare's P/E is 67.90. With facilities located in India 165 and internationally 15 (including 9 in Africa), Tamil Nadu -based firm optical products, contact lenses, accessories and eye care pharmaceuticals, besides selling pharmaceuticals to eye care Provides By FY 2024, it had about 25% of the overall eye care service market share in India. The eye care sector in India is estimated to expand from the compound annual growth rate (CAGR) of 12–14% from FY 24 to FY 28.

According to Dr. Aggarwal Healthcare's draft documents, the value of the Indian Eye Care Service market in FY 2024 was around ₹ 37,800 crore and by FY 28 it is expected to reach between ₹ 55,000 to ₹ 65,000 crore by FY 28. Here are 10 main things to know about Dr. Aggarwal Healthcare IPO. Date of Dr. Aggarwal Healthcare IPO: Dr. Aggarwal IPO will open for subscription on Wednesday, January 29 and will close on Friday, January 31. Price band of Dr. Aggarwal Healthcare IPO: Dr. Aggarwal IPO has been fixed at the limit of ₹ 382 to ₹ 402 for equity share per one rupee value. Dr. Aggarwal Healthcare IPO's lot size: Dr. Aggarwal IPO's lot size is 35 equity share and then in the multiples of 35 equity shares. Anchor Investor: Allotment to anchor investors for Dr. Aggarwal IPO is going to be held today (Tuesday, 28 January). Details of Dr. Aggarwal Healthcare IPO: Dr. Aggarwal Healthcare IPO will be issued new equity shares of ₹ 300 crore, along with 6.78 crore shares worth ₹ 2,727.3 crore will be sold from existing stakeholders. In addition to promoters, the stakeholders involved in the sales include the Arvon Investments PTE and Clemore Investments Mauritius PTE, both private equity firms are associated with Temasic Holdings, and Hyperian Investments PTE, which is associated with US Private Equity Firm TPG.

Public shareholders are represented by Aurwon Investments PTE, which have 12.44% shares, Claimor Investments Mauritius PTE, which holds 15.71%, and Hyperian Investments PTE, which has 33.70% stake, while the promoter company has 37.73% at 37.73% Keep control. Dr. Aggarwal Healthcare IPO Purpose: With the net income of the new offering, the company aims to allocate ₹ 195 crore for repayment of loan. The remaining amount will also be directed to undeclared inorganic acquisitions and general business requirements.

Dr. Aggarwal Healthcare IPO Listing Date and Allocation Details: The allocation of shares of Dr. Aggarwal Healthcare IPO will be decided on Monday, February 3 and the company will start refund on Tuesday, February 4, while on the same day after refund of shares allottees Demat will be deposited in the account. The price of Dr. Aggarwal Healthcare's stock is likely to be listed on BSE and NSE on Wednesday, 5 February.

Dr. Aggarwal Healthcare IPO Chief Manager and Registrar: The main book-ringing lead manager for Dr. Agarwal IPO is Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Ltd. Caffeine Technologies Limited works as the Registrar of this issue.

Dr. Aggarwal Healthcare IPO Reservation: Dr. Aggarwal IPO has not reserved more than 50% shares in public issue for qualified institutional buyers (QIB), no less than 15% for non-institutional institutional investors (NIIs), and Retail has reserved not less than 35% of the proposal for investors. Employees Part 1,579,399 have been reserved up to equity shares, and shareholders are reserved to 1,129,574.